Targets › GP160
2 programs from 1 company in 3 trials: 3 Phase 1; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on GP160, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | CH505 TF mRNA-gp160 mRNA-gp160 encapsulated in lipid nanoparticles (LNPs) expressing HIV envelope protein to b | GP160 | Phase 1 | HIV Infections; HIV | Mar 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | CH505M5 N197D mRNA-gp160 mRNA-gp160 encapsulated in lipid nanoparticles (LNPs) expressing HIV envelope protein to i | GP160 | Phase 1 | HIV Infections | Mar 2027 |
HIV Infections (2) HIV (1)
other (2)
National Institute of Allergy and Infectious Diseases (NIAID) (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.